Please login to the form below

Not currently logged in
Email:
Password:

Ablynx appoints Markus Ewert as chief business officer

He will also join the Belgium-based biopharma firm's executive committee

Markus EwertGhent, Belgium-based biopharmaceutical company Ablynx has appointed Markus Ewert as chief business officer, a role that will see him drive business development and corporate strategy activities.

He has nearly 30 years’ experience in the life sciences industry, with his most recent role as head of the business development team of the healthcare division at General Electric.

Edwin Moses, CEO of Ablynx, said: “Markus brings extensive experience in leading business development teams and executing licensing deals and acquisitions.

“Having held senior positions in big pharma as well as in biotech and consultancy firms, he is ideally suited to become part of our executive committee and play an important role in helping Ablynx achieve its business objectives.”

Prior to his time at GE, Ewert served at Novartis within its cardiovascular and metabolism franchise and subsequently moved to its molecular diagnostics unit as head of strategy.

Ewert was also CEO of two biotech companies and has served as an advisor to pharmaceutical and chemical companies at The Boston Consulting Group.

He said: “I am very excited to join the Ablynx team and lead their business development and strategy activities.

“I am looking forward to strengthening the company’s existing relationships with pharmaceutical companies, creating new partnering and strategic opportunities to further build the product pipeline, and advancing the company.”

15th June 2017

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
PRMA Consulting Ltd

PRMA Consulting is an independent consultancy solving some of the most challenging pricing, reimbursement and market access issues facing international...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics